StockData
MediWound Ltd. logo

MediWound Ltd. (MDWD) shareholders

MDWDNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 5, 2026Score 2/30
$13.55+0.65 (+5.04%)

Close on Nov 16, 2026Market cap $173.92MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
45.3%
6M of 13M shares
Institutional holders
79
15 new, 10 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
7 buys · 4 sales
Net bought $60.61K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Access Industries Holdings LLC
Joint filing with Access Industries, LLC (11.56%), Access Industries Management, LLC (11.56%) and 4 more
1,481,52111.56%13D (active) amendmentSep 30, 2025
HOLD Alapkezelo Zrt.1,348,32310.40%13G (passive) amendmentAug 27, 2026
/ . Israel Biotech Fund II, L.P.
Joint filing with / . Israel Biotech Fund GP Partners II, L.P. (10.40%), / . I.B.F Management Ltd. (10.40%)
959,65210.40%13G (passive) amendmentDec 31, 2023
/ . Deep Insight Management Ltd.
Joint filing with / . Deep Insight Limited Partnership (10.40%), / . Deep Insight Fund GP Limited Partnership (10.40%) and 3 more
959,65210.40%13G (passive) amendmentDec 31, 2023
Aharon Gil
Joint filing with Rosalind Advisors, Inc. (7.00%), Salamon Steven A J (7.00%) and 1 more
912,3197.00%13G (passive) amendmentDec 31, 2025
Patricia Industries AB
Joint filing with Mölnlycke Health Care AB (8.10%), MHC Sweden AB (8.10%) and 4 more
872,0938.10%13D (active)Jul 17, 2024
Salamon Steven A J
Joint filing with Rosalind Advisors, Inc. (7.20%), Aharon Gil (7.20%) and 1 more
791,3157.20%13G (passive) amendmentDec 31, 2024
Dov Yelin
Joint filing with Yelin Lapidot Holdings Management Ltd. (5.95%), Yair Lapidot (5.95%)
763,0695.95%13G (passive) amendmentDec 31, 2025
T. Rowe Price Associates, Inc.641,0755.00%13G (passive) amendmentJun 30, 2026
Rosalind Advisors, Inc.
Joint filing with Salamon Steven A J (5.20%), Aharon Gil (5.20%) and 1 more
570,3265.20%13G (passive) amendmentJun 30, 2025
1,481,521 12 Check Box If The Aggregate Amount In Row (11) Excludes Certain Shares: ☐ 13 Percent Of Class Represented By Amount In Row (11): 13.8%* 14 Type Of
Joint filing with 1,172,710 12 Check Box If The Aggregate Amount In Row (11) Excludes Certain Shares: ☒ 13 Percent Of Class Represented By Amount In Row (11): 10.92%* 14 Type Of (10.92%)
–13.80%13D (active) amendmentJul 17, 2024

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of MDWDValueChange% of portfolio
Investor Ab872,0936.79%$12.82M–0.09%
Yelin Lapidot Holdings Management Ltd.758,1695.91%$11.15M−4,6482.11%
Rosalind Advisors, Inc.749,0545.84%$11.01M–4.09%
Price T Rowe Associates Inc /Md/641,0754.99%$9.43M−68,7720.00%
BlackRock, Inc.525,9294.10%$7.73M+80,0950.00%
Sphera Funds Management Ltd.273,1922.13%$4.02M–0.52%
Silverberg Bernstein Capital Management LLC228,1371.78%$3.35M+28,1321.28%
State Street Corp168,6691.31%$2.48M+24,8990.00%
UBS Group AG155,9221.21%$2.29M−3,8690.00%
Geode Capital Management, LLC141,0411.10%$2.07M+19,0830.00%
Point72 Asset Management, L.P.129,2481.01%$1.90M−46,2310.00%
ARK Investment Management LLC126,5760.99%$1.86M−3,3850.01%
Northern Trust Corp112,1910.87%$1.65M−9,5850.00%
DAFNA Capital Management LLC94,4050.74%$1.39M–0.26%
Morgan Stanley88,6600.69%$1.30M+1870.00%
Clal Insurance Enterprises Holdings Ltd71,0000.55%$1.04M–0.00%
Vanguard Portfolio Management LLC70,1430.55%$1.03M+12,5960.00%
Sargent Investment Group, LLC62,4810.49%$918.47K+3,0000.11%
Citadel Advisors LLC58,4960.46%$859.89K−7440.00%
Aqr Capital Management LLC50,3570.39%$740.25KNew0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026796M45.3%15 / 2919 / 100M1M
Q1 2026766M47.1%17 / 2718 / 171M0M
Q4 2025786M48.4%15 / 3117 / 101M0M
Q3 2025766M45.0%18 / 3014 / 102M0M
Q2 2025684M34.6%9 / 1925 / 50M0M
Q1 2025644M33.4%10 / 2518 / 90M0M
Q4 2024644M34.5%7 / 2513 / 50M0M
Q3 2024634M32.8%22 / 1617 / 32M0M
Q2 2024453M21.1%19 / 109 / 51M0M
Q1 2024312M17.7%13 / 115 / 41M1M
Q4 2023223M19.6%7 / 47 / 31M0M
Q3 2023182M15.9%1 / 39 / 20M0M

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Ofer GonenChief Executive Officer66,0190.51%Nov 12, 2026
Shmuel HessCOO & Chief Commercial Officer0–Aug 28, 2026
Ety KlingerChief Medical Officer1,5000.01%Mar 18, 2026
Yaron MeyerEVP, GC & Corp. Secretary2,3570.02%Mar 18, 2026
Yaakov Aya BenVP Clinical & Reg. Affairs1250.00%Mar 18, 2026
Kalfon Hana LuxenburgChief Financial Officer3,0000.02%Mar 18, 2026
Nachum ShamirDirector72,1510.56%Nov 12, 2026
David Morton FoxDirector28,8170.22%Nov 12, 2026
Samuel RubinsteinDirector7500.01%Sep 2, 2026
Vickie Rae DriverDirector7500.01%Mar 25, 2026
Stephen T. WillsDirector7500.01%Mar 18, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Ofer Gonen
Chief Executive Officer
Nov 11, 2026Option exercise+8,168$13.47$110.06K66,019
Nachum Shamir
Director
Nov 10, 2026Option exercise+16,336$13.47$220.13K72,151
David Morton Fox
Director
Nov 10, 2026Option exercise+6,534$13.47$88.05K28,817
Samuel Rubinstein
Director
Sep 1, 2026Sale−525$12.72$6.68K0
Samuel Rubinstein
Director
Sep 1, 2026Buy+525$12.62$6.63K525
Shmuel Hess
COO & Chief Commercial Officer
Aug 27, 2026Sale−1,979$12.72$25.17K0
Shmuel Hess
COO & Chief Commercial Officer
Aug 27, 2026Sale−1,979$13.13$25.98K0
Shmuel Hess
COO & Chief Commercial Officer
Aug 26, 2026Sale−1,865$13.00$24.25K0
Nachum Shamir
Director
Jun 3, 2026Buy+5,825$14.00$81.55K55,815
Nachum Shamir
Director
Jun 3, 2026Buy+175$13.98$2.45K49,990
David Morton Fox
Director
Jun 1, 2026Buy+1,797$14.00$25.16K22,283
David Morton Fox
Director
Jun 1, 2026Buy+10$14.23$14220,486
David Morton Fox
Director
Jun 1, 2026Buy+1,730$14.23$24.62K20,476
Samuel Rubinstein
Director
May 29, 2026Buy+150$14.33$2.15K2,993

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
18.22%
2M shares short
Days to cover
14.7
At 0M shares a day
Change since last report
+2.3%
From 2M shares
Short volume, 20 days
54.4%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of MediWound's stock actually held short. Settlement fails (shares not delivered on time) peaked at 37,471 shares on Aug 28, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Shmulik Hess
Officer
Aug 28, 20263,958$50.27KAug 27, 2026Shares acquired upon exercise of employee stock options
Shmuel Hess
Officer
Dec 3, 20253,693$63.56KDec 2, 2025Employee Stock Option Plan

See a number that looks wrong?